Solifenacin at 3 Years: A Review of Efficacy and Safety
Authors:
- Richard S. PelmanRPRichard S. Pelman
- James P. CapoJCJames P. Capo
- Sergio Forero-SchwanhaeuserSFSergio Forero-Schwanhaeuser
- 1 January 2008
- journal article
- review article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 120 (2) , 85-91
Abstract
Now on the market in the United States for almost 3 years and available in 48 countries worldwide, solifenacin 5 mg or 10 mg once daily continues to demonstrate a profile of safety and efficacy as a treatment for incontinence, urgency, and other symptoms of OAB. More than 2.2 million patients have been treated worldwide with solifenacin. Safety and efficacy data across numerous studies in several thousand patients, along with flexible dosing, support the use of this agent as a first-line antimuscarinic treatment for OAB. Data from large randomized controlled trials such as VENUS and STAR show statistically significant superiority compared with placebo and improved outcomes over those achieved with tolterodine ER 4 mg. Solifenacin is an agent of choice for OAB-related incontinence, with more than 50% of incontinent patients reporting no incontinence episodes after 12 weeks of solifenacin therapy. In addition to improved efficacy, solifenacin offers good tolerability with a low incidence of side effects. Once-daily, flexible dosing with this agent provides 24-hour control of OAB symptoms and significantly increases warning time (the period from onset of urgency to voiding), which may also increase a patient's chance of avoiding episodes of incontinence.Keywords
This publication has 14 references indexed in Scilit:
- Multiple doses of the antimuscarinic agent solifenacin do not affect the pharmacodynamics or pharmacokinetics of warfarin or the steady-state pharmacokinetics of digoxin in healthy subjectsBritish Journal of Clinical Pharmacology, 2006
- Solifenacin significantly improves all symptoms of overactive bladder syndromeInternational Journal Of Clinical Practice, 2006
- Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: A pooled analysisThe American Journal of Geriatric Pharmacotherapy, 2006
- Pharmacologic Management of Overactive Bladder: Practical Options for the Primary Care PhysicianThe American Journal of Medicine, 2006
- Muscarinic receptors in the bladder: from basic research to therapeuticsBritish Journal of Pharmacology, 2006
- Vaginal mesh erosion after transvaginal repair of cystocele using Gynemesh or Gynemesh-Soft in 138 women: a comparative studyInternational Urogynecology Journal, 2006
- A Comparison of the Efficacy and Tolerability of Solifenacin Succinate and Extended Release Tolterodine at Treating Overactive Bladder Syndrome: Results of the STAR TrialEuropean Urology, 2005
- Long-Term Open-Label Solifenacin Treatment Associated with Persistence with Therapy in Patients with Overactive Bladder SyndromeEuropean Urology, 2005
- Recent developments in the management of overactive bladder: focus on the efficacy and tolerability of once daily solifenacin succinate 5 mgCurrent Medical Research and Opinion, 2004
- Solifenacin appears effective and well tolerated in patients with symptomatic idiopathic detrusor overactivity in a placebo‐ and tolterodine‐controlled phase 2 dose‐finding studyBJU International, 2003